ES2558565T3 - Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) - Google Patents
Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) Download PDFInfo
- Publication number
- ES2558565T3 ES2558565T3 ES02727946.2T ES02727946T ES2558565T3 ES 2558565 T3 ES2558565 T3 ES 2558565T3 ES 02727946 T ES02727946 T ES 02727946T ES 2558565 T3 ES2558565 T3 ES 2558565T3
- Authority
- ES
- Spain
- Prior art keywords
- atorvastatin
- width
- diffractometer
- phenylamino
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una forma VII cristalina de atorvastatina sesquihidratada que tienen una difracción de rayos X de polvo que contiene los siguientes valores de 2θ medidos usando radiación CuKα: 8,6, 10,2, 12,4 (ancho), 12,8 (ancho), 17,6, 18,3 (ancho), 19,3, 22,2 (ancho), 23,4 (ancho), 23,8 (ancho) y 25,5 (ancho).
Description
Adicionalmente, la presente invención se refiere a la forma VII cristalina de atorvastatina sesquihidratada caracterizada mediante el siguiente espectro Raman que tiene picos expresados en cm-1:
Espectro Raman 3060 2927 1649 1603 1524 1476 1412 1397 1368 1159 1034 998 824 114
La forma VIII cristalina de atorvastatina e hidratos de la misma se caracterizan por el siguiente patrón de difracción de rayos X de polvo expresado en términos de 2θ e intensidades relativas con una intensidad relativa de >10 % medida con un difractómetro Shimadzu con radiación CuKα:
2θ Intensidad relativa (>10 %)a
- 7,5
- 61
- 9,2
- 29
- 10,0
- 16
- 12,1
- 10
- 12,8
- 6
- 13,8
- 4
- 15,1
- 13
- 16,7 (ancho)
- 64
- 18,6 (ancho)
- 100
- 20,3 (ancho)
- 79
- 21,2
- 24
- 21,9
- 30
- 22,4
- 19
- 25,8
- 33
- 26,5
- 20
- 27,4 (ancho)
- 38
- 30,5
- 20
a Intensidad relativa de 12,8 2θ es 6 y 13,8 2θ es 4.
10 Adicionalmente, el siguiente patrón de difracción de rayos X de polvo de la forma VIII cristalina de atorvastatina expresada en términos de valores de 2θ se midió en un difractómetro Inel (capilar):
2θ
7,5
9,3
10,1
12,2
12,8
7
- 9,9
- 36
- 10,4 (ancho)
- 24
- 12,5
- 18
- 13,9 (ancho)
- 9
- 16,2
- 10
- 17,8
- 70
- 19,4
- 100
- 20,8
- 51
- 21,7
- 13
- 22,4-22,6 (ancho)
- 18
- 24,3
- 19
- 25,5
- 24
- 26,2
- 11
- 27,1
- 8
a Intensidad relativa de 13,9 (ancho) 2θ es 9y 27,12θ es 8.
Adicionalmente, el siguiente patrón de difracción de rayos X de polvo de la forma cristalina XII de atorvastatina expresada en términos de valores de 2θ se midió en un difractómetro Inel (capilar):
2θ 5,4 7,7 8,1 8,6 8,9 10,0 10,5 12,6 14,0 (ancho) 2θ 16,2 17,9 19,4 20,9 21,8 22,5-22,8 (ancho)
24,4
25,6 26,4 27,2
Adicionalmente, la forma cristalina XII de atorvastatina e hidratos de la misma se caracterizan mediante el siguiente espectro Raman que tiene picos expresados en cm-1:
Espectro Raman 3064 2973 2926 1652 1603 1527
12
5
15
25
35
45
55
65
Figura 10 Difractograma de la Forma XIV de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 11 Difractograma de la Forma XV de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 12 Difractograma de la Forma XVI de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 13 Difractograma de la Forma XVII de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 14 Difractograma de la Forma XVIII de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 15 Difractograma de la Forma XIX de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 16 Difractograma de la Forma V de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 17 Difractograma de la Forma VI de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 18 Difractograma de la Forma VII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 19 Difractograma de la Forma VIII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 20 Difractograma de la Forma IX de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 21 Difractograma de la Forma X de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 22 Difractograma de la Forma XII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 23 Difractograma de la Forma XVI de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 24 Difractograma de la Forma XVIII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 25 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma V de atorvastatina.
Figura 26 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VI de atorvastatina.
Figura 27 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VII de atorvastatina.
Figura 28 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VIII de atorvastatina.
Figura 29 Espectro de resonancia magnética nuclear de 13C en estado sólido de la Forma X de atorvastatina.
Figura 30 Espectro Raman de la Forma V.
17
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30204901P | 2001-06-29 | 2001-06-29 | |
US302049P | 2001-06-29 | ||
PCT/IB2002/001796 WO2003004470A1 (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2558565T3 true ES2558565T3 (es) | 2016-02-05 |
Family
ID=23166039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02727946.2T Expired - Lifetime ES2558565T3 (es) | 2001-06-29 | 2002-05-21 | Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) |
Country Status (40)
Country | Link |
---|---|
US (5) | US6605729B1 (es) |
EP (2) | EP1423364B1 (es) |
JP (2) | JP3965155B2 (es) |
KR (1) | KR100609371B1 (es) |
CN (2) | CN1524073A (es) |
AP (1) | AP1571A (es) |
AR (1) | AR036118A1 (es) |
AU (1) | AU2002258092B2 (es) |
BG (1) | BG108393A (es) |
BR (1) | BR0210666A (es) |
CA (1) | CA2450111C (es) |
CR (2) | CR7170A (es) |
CZ (1) | CZ20033478A3 (es) |
DO (1) | DOP2002000413A (es) |
EA (1) | EA005317B1 (es) |
EC (1) | ECSP034928A (es) |
EE (1) | EE200300597A (es) |
ES (1) | ES2558565T3 (es) |
GE (1) | GEP20053546B (es) |
HR (1) | HRP20031039A2 (es) |
HU (1) | HUP0400381A2 (es) |
IL (1) | IL158790A0 (es) |
MA (1) | MA27044A1 (es) |
MX (1) | MXPA03010266A (es) |
MY (1) | MY122907A (es) |
NO (1) | NO326170B1 (es) |
NZ (1) | NZ529557A (es) |
OA (1) | OA12636A (es) |
PA (1) | PA8549501A1 (es) |
PE (1) | PE20030124A1 (es) |
PL (1) | PL367943A1 (es) |
RS (1) | RS100003A (es) |
SK (1) | SK16002003A3 (es) |
SV (1) | SV2003001144A (es) |
TN (1) | TNSN03147A1 (es) |
TW (1) | TWI319396B (es) |
UA (1) | UA74075C2 (es) |
UY (1) | UY27359A1 (es) |
WO (1) | WO2003004470A1 (es) |
ZA (1) | ZA200308731B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
US20040072138A1 (en) * | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US20080275104A1 (en) * | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
IL155734A0 (en) * | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2623599A1 (en) * | 2000-12-27 | 2002-07-04 | Paul Adrian Van Der Schaaf | Crystalline forms of atorvastatin |
CN1524073A (zh) * | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀) |
US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2003070702A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
KR20090045419A (ko) * | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
CA2491051A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
AU2003297594A1 (en) * | 2002-11-28 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
JP2007516294A (ja) * | 2003-12-23 | 2007-06-21 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 炎症性の疾患または症状の予防および治療のための方法および組成物 |
WO2005090301A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
FI120344B (fi) | 2004-03-17 | 2009-09-30 | Ranbaxy Lab Ltd | Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi |
WO2005105738A2 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of atorvastatin |
CA2754932C (en) * | 2004-07-20 | 2014-04-01 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
KR100881103B1 (ko) * | 2004-09-28 | 2009-02-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법 |
MX2007004722A (es) * | 2004-10-28 | 2007-06-15 | Warner Lambert Co | Procedimiento para formar atorvastatina amorfa. |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
US20090208539A1 (en) * | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
US20090088465A1 (en) * | 2004-12-02 | 2009-04-02 | Stephen Craig Dyar | Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same |
EP1688850A1 (en) | 2005-02-07 | 2006-08-09 | Sony Ericsson Mobile Communications AB | Generic parser for electronic devices |
US8506646B2 (en) * | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
US8092464B2 (en) * | 2005-04-30 | 2012-01-10 | Warsaw Orthopedic, Inc. | Syringe devices and methods useful for delivering osteogenic material |
WO2007057755A1 (en) | 2005-11-21 | 2007-05-24 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium |
EP1923057A1 (en) * | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Atorvastatin pharmaceutical formulation |
CA2628666A1 (en) * | 2005-11-21 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Atorvastatin formulation |
KR20100023059A (ko) * | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
KR100878140B1 (ko) | 2007-01-29 | 2009-01-12 | 한미약품 주식회사 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
CA2679317A1 (en) * | 2007-03-02 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel crystal forms of pyrrolylheptanoic acid derivatives |
WO2008112887A1 (en) * | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
WO2008123953A1 (en) * | 2007-04-02 | 2008-10-16 | Merck & Co., Inc. | Anti-hypercholesterolemic compound |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
CN102976996B (zh) * | 2009-05-27 | 2015-08-19 | 峡江和美药业有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
MX2013015272A (es) | 2011-07-01 | 2014-04-14 | Dsm Sinochem Pharm Nl Bv | Cristales micronizados. |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
US10450957B2 (en) | 2017-01-23 | 2019-10-22 | United Technologies Corporation | Gas turbine engine with heat pipe system |
WO2020013330A1 (ja) * | 2018-07-13 | 2020-01-16 | 協和発酵バイオ株式会社 | ユーコミン酸の非溶媒和物結晶及びその製造方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
WO1994016693A1 (en) | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
US5998633A (en) | 1996-07-29 | 1999-12-07 | Warner-Lambert Company | Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid |
IN191236B (es) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
WO2001036384A1 (en) * | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
EP1237865B1 (en) * | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
AU780247B2 (en) * | 1999-12-17 | 2005-03-10 | Pfizer Science And Technology Ireland Limited | A process for producing crystalline atorvastatin calcium |
IL155734A0 (en) * | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
PT1341785E (pt) * | 2000-11-16 | 2009-01-16 | Teva Pharma | Hidrólise de ésteres de ácidos r(r*,r*)-2-(4-fluorofenil)-beta,delta-di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico com hidróxido de cálcio |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2623599A1 (en) * | 2000-12-27 | 2002-07-04 | Paul Adrian Van Der Schaaf | Crystalline forms of atorvastatin |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
CN1524073A (zh) * | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀) |
US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
KR20100023059A (ko) * | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
-
2002
- 2002-05-21 CN CNA028130227A patent/CN1524073A/zh active Pending
- 2002-05-21 CA CA002450111A patent/CA2450111C/en not_active Expired - Fee Related
- 2002-05-21 EP EP02727946.2A patent/EP1423364B1/en not_active Expired - Lifetime
- 2002-05-21 HU HU0400381A patent/HUP0400381A2/hu unknown
- 2002-05-21 GE GE5360A patent/GEP20053546B/en unknown
- 2002-05-21 BR BR0210666-3A patent/BR0210666A/pt not_active IP Right Cessation
- 2002-05-21 SK SK1600-2003A patent/SK16002003A3/sk unknown
- 2002-05-21 CN CNA2007101598559A patent/CN101215253A/zh active Pending
- 2002-05-21 WO PCT/IB2002/001796 patent/WO2003004470A1/en active Application Filing
- 2002-05-21 JP JP2003510638A patent/JP3965155B2/ja not_active Expired - Fee Related
- 2002-05-21 IL IL15879002A patent/IL158790A0/xx unknown
- 2002-05-21 AP APAP/P/2003/002936A patent/AP1571A/en active
- 2002-05-21 NZ NZ529557A patent/NZ529557A/en unknown
- 2002-05-21 PL PL02367943A patent/PL367943A1/xx not_active Application Discontinuation
- 2002-05-21 MX MXPA03010266A patent/MXPA03010266A/es active IP Right Grant
- 2002-05-21 EP EP15192682.1A patent/EP3009423A3/en not_active Withdrawn
- 2002-05-21 EE EEP200300597A patent/EE200300597A/xx unknown
- 2002-05-21 UA UA20031212658A patent/UA74075C2/uk unknown
- 2002-05-21 KR KR1020037016944A patent/KR100609371B1/ko not_active IP Right Cessation
- 2002-05-21 EA EA200301243A patent/EA005317B1/ru not_active IP Right Cessation
- 2002-05-21 CZ CZ20033478A patent/CZ20033478A3/cs unknown
- 2002-05-21 OA OA1200300342A patent/OA12636A/en unknown
- 2002-05-21 AU AU2002258092A patent/AU2002258092B2/en not_active Ceased
- 2002-05-21 RS YUP-1000/03A patent/RS100003A/sr unknown
- 2002-05-21 ES ES02727946.2T patent/ES2558565T3/es not_active Expired - Lifetime
- 2002-06-05 DO DO2002000413A patent/DOP2002000413A/es unknown
- 2002-06-26 PE PE2002000569A patent/PE20030124A1/es not_active Application Discontinuation
- 2002-06-27 UY UY27359A patent/UY27359A1/es not_active Application Discontinuation
- 2002-06-28 SV SV2002001144A patent/SV2003001144A/es not_active Application Discontinuation
- 2002-06-28 AR ARP020102428A patent/AR036118A1/es unknown
- 2002-06-28 TW TW091114336A patent/TWI319396B/zh not_active IP Right Cessation
- 2002-06-28 US US10/184,669 patent/US6605729B1/en not_active Expired - Lifetime
- 2002-06-28 MY MYPI20022466A patent/MY122907A/en unknown
- 2002-06-28 PA PA20028549501A patent/PA8549501A1/es unknown
-
2003
- 2003-06-06 US US10/456,046 patent/US7144915B2/en not_active Expired - Lifetime
- 2003-07-08 TN TNPCT/IB2002/001796A patent/TNSN03147A1/fr unknown
- 2003-11-10 ZA ZA200308731A patent/ZA200308731B/en unknown
- 2003-11-26 CR CR7170A patent/CR7170A/es not_active Application Discontinuation
- 2003-11-28 BG BG108393A patent/BG108393A/bg unknown
- 2003-12-16 HR HR20031039A patent/HRP20031039A2/xx not_active Application Discontinuation
- 2003-12-18 NO NO20035675A patent/NO326170B1/no unknown
- 2003-12-22 MA MA27456A patent/MA27044A1/fr unknown
- 2003-12-29 EC EC2003004928A patent/ECSP034928A/es unknown
-
2006
- 2006-05-25 US US11/441,268 patent/US20060241169A1/en not_active Abandoned
-
2007
- 2007-04-11 JP JP2007103465A patent/JP2007182460A/ja active Pending
- 2007-10-25 US US11/977,459 patent/US20080214651A1/en not_active Abandoned
-
2008
- 2008-02-15 CR CR9741A patent/CR9741A/es not_active Application Discontinuation
- 2008-07-14 US US12/172,503 patent/US20080287521A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2558565T3 (es) | Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) | |
CO4700442A1 (es) | Forma iii cristalina de sal de calcio de acido [r-(r*,r*)] -2-(4-fluorofenil)-b,s-dihidroxi-5-(1-metiletil)-3-fenil-4- [(fenilamino)carbonil] -1h-pirrol-1-heptanoico (2:1) | |
NZ527048A (en) | Crystalline forms of atorvastatin | |
BR0116785A (pt) | Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários | |
GEP20002029B (en) | (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin) | |
AU4150602A (en) | Atorvastatin hemi-calcium form vii | |
DE60043807D1 (de) | Umsetzung des Farbtonbereichs mit Erhaltung der lokalen Luminanzdifferenzen durch adaptives örtliches Filtern | |
DE60213939D1 (de) | Zylinderkopfdichtung | |
MXPA04000889A (es) | Formas cristalinas vi y vii de atorvastatina calcica. | |
DE59811409D1 (de) | Metallische Zylinderkopfdichtung | |
DE50207418D1 (de) | Zylinderkopfdichtung | |
ATE393123T1 (de) | Herstellung von eisenverbindungen durch hydrothermale umwandlung | |
DE60204997D1 (de) | Zylinderkopfdichtung mit Umfangwulst | |
AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
DE10137548B4 (de) | Zylinderkopfdichtung | |
DE59810326D1 (de) | Metallische Zylinderkopfdichtung | |
CA2521776A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
RU2003108341A (ru) | Способ изготовления замка и замок | |
FR2829196B1 (fr) | Labyrinthe d'accrochage pour piton escamotable a double verrouillage | |
RU99108621A (ru) | Суспензия для изготовления пресс-порошков магний-цинковых ферритов распылительной сушкой | |
RU2001104292A (ru) | Пневмоцилиндр | |
RU2001106870A (ru) | Способ получения пигмента черного цвета | |
RU2002124897A (ru) | Управляемый резонатор № 1 | |
RU99111535A (ru) | Радиопоглощающий материал | |
TH56836EX (th) | เตาอบไมโครเวฟ |